Codice QR

Immune checkpoint inhibitors in pancreatic adenocarcinoma: a systematic review and meta analysis of clinical outcomes

BackgroundPancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with poor outcomes despite therapeutic advancements. Immune checkpoint inhibitors (ICIs) have transformed cancer care, but their efficacy in PDAC is limited due to the tumor’s immunosuppressive microen...

Descrizione completa

Salvato in:
Autori principali: Aisha Al-Khinji, Noora Al-Korbi, Sheikha Al-Kuwari, Abdullatif Al-Hor, Dhafer Malouche
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2025-08-01
Serie:Frontiers in Oncology
Soggetti:
pancreatic ductal adenocarcinoma (PDAC)
immune checkpoint inhibitors (ICIs)
tumor mutational burden
combination therapy
survival outcomes
Accesso online:https://www.frontiersin.org/articles/10.3389/fonc.2025.1569884/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi